Skip to main content

Top navigation

  • GSA Award
  • For Veterans
  • HCP Portal
  • Pay My Bill Online
  • Contact Us
  • +1 844 396 7663
Bio-Techne Exosome logo

Main navigation

  • Physicians
    • How to Order the ExoDx™ Prostate Test
    • ExoDx™ Prostate Test: At-Home Collection Kit
    • ExoDx™ Prostate Test
    • Challenge of Prostate Cancer
    • Physician FAQs
    • What are Exosomes
    • Publications and Abstracts
    • mpMRI + ExoDx Prostate Test
  • Patients
    • The ExoDx Prostate Test
    • How to Order the ExoDx™ Prostate Test
    • Physician Finder
    • Understanding PSA Levels
    • Elevated PSA Levels
    • Normal PSA Levels & PSA Levels by Age
    • About Prostate Cancer
    • ZERO - The End of Prostate Cancer
    • Patient FAQs
    • ExoCARES Program
  • Pharma Services
    • Working with Us
    • Biomarker Discovery
    • Assay Development
    • Exosome Enrichment Capabilities
    • Companion Diagnostics (CDx) and Clinical Trial Support
  • Our Technology
    • Our Technology
    • Sensitivity to RNA/DNA
    • Extraction Procedures
    • Superiority to cfDNA and CTCs
  • News & Resources
    • Literature
    • Press
    • Webinars
    • Events
    • Newsletters

Top navigation

  • GSA Award
  • For Veterans
  • HCP Portal
  • Pay My Bill Online
  • Contact Us
  • +1 844 396 7663

Press

  • Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients

    Press Mar 20, 2018

  • Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor

    Press Mar 14, 2018

  • Exosome Diagnostics Expands its Coverage Reach for EPI to an Additional 82 Million Covered Lives in the United States

    Press Feb 23, 2018

  • Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed

    Press Feb 01, 2018

  • Exosome Diagnostics Executes Agreement with America’s Choice Provider Network Expanding Access and Coverage for EPI to 28 Million Member Network in the US

    Press Jan 25, 2018

  • Exosome Diagnostics Places Early Access Shahky™ Exosomal Protein Detection System at MGH Center for Systems Biology

    Press Jan 09, 2018

  • Exosome Diagnostics Launches National Sales Team to Support Flagship Test, ExoDx®Prostate(IntelliScore)

    Press Jan 04, 2018

  • Exosome Diagnostics Publishes a Study Demonstrating Superior Performance of ExoLution™ Plus Liquid Biopsy Platform in Lung Cancer

    Press Dec 19, 2017

  • Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network

    Press Dec 04, 2017

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4

(844) 396-7663
exosomedx.info@bio-techne.com
266 Second Ave, Suite 200
Waltham, MA 02451

Footer menu

  • About Bio-Techne
  • Management Team
  • Careers
  • Investors
  • Corporate Responsibility
  • Accreditation and Licensure

Social navigation

  • Facebook
  • Twitter
  • LinkedIn

The ExoDx Prostate Test was evaluated and its performance characteristics determined by Exosome Diagnostics, Inc. Exosome Diagnostics is certified under the Clinical Laboratory Improvement Amendments (CLIA) Act of 1988 as qualified to perform high complexity clinical testing. CLIA number: 22D2093470.  Exosome Diagnostics and ExoDx are registered trademarks of Exosome Diagnostics, Inc.

© 2025 ExoDx

Bottom footer navigation

  • Privacy Policy